Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation

被引:25
作者
Clements, IP [1 ]
Davis, BJ [1 ]
Wiseman, GA [1 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA
关键词
diastolic dysfunction; doxorubicin cardiotoxicity;
D O I
10.1097/00006231-200206000-00003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Diastolic and systolic left ventricular (LV) function may be affected early after the initiation of doxorubicin therapy. However, the role of mediastinal radiation and other cytotoxic agents in the production of these early cardiac effects is unclear. In this study LV diastolic and systolic function were assessed before and after doxorubicin (223 +/- 122 mg.m(-2); range, 40-618) in 33 patients. After doxorubicin, LV ejection fraction declined (0.61 +/- 0.08 to 0.56 +/- 0.08, P = 0.0008), peak filling rate decreased (3.38 +/- 1.10 to 2.82 +/- 0.62 end diastolic volumes/s, P = 0.006), and time to peak filling rate increased (162 +/- 39 to 182 +/- 45 ms, P = 0.04). The changes in LV systolic and diastolic function were not related to doxorubicin dose and the use of other cytotoxic agents; the decrease in LV ejection fraction with doxorubicin was more notable in men and in patients who received mediastinal irradiation concurrently with doxorubicin. It is concluded that the use of doxorubicin was associated with the simultaneous early development of LV systolic and diastolic dysfunction. Male gender and concurrent mediastinal irradiation were independent influences, but doxorubicin dose and the use of other cytotoxic agents were not associated with worse cardiac dysfunction. ((C) 2002 Lippincott Williams Wilkins).
引用
收藏
页码:521 / 527
页数:7
相关论文
共 21 条
[1]   SERIAL ASSESSMENT OF DOXORUBICIN CARDIOTOXICITY WITH QUANTITATIVE RADIONUCLIDE ANGIOCARDIOGRAPHY [J].
ALEXANDER, J ;
DAINIAK, N ;
BERGER, HJ ;
GOLDMAN, L ;
JOHNSTONE, D ;
REDUTO, L ;
DUFFY, T ;
SCHWARTZ, P ;
GOTTSCHALK, A ;
ZARET, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (06) :278-283
[2]  
BHAGWAT AR, 1997, CARDIAC NUCL MED, P427
[3]   DOSE-EFFECT AND STRUCTURE-FUNCTION-RELATIONSHIPS IN DOXORUBICIN CARDIOMYOPATHY [J].
BRISTOW, MR ;
MASON, JW ;
BILLINGHAM, ME ;
DANIELS, JR .
AMERICAN HEART JOURNAL, 1981, 102 (04) :709-718
[4]   DIASTOLIC MEASUREMENTS FROM ALTERNATE R-WAVE GATING OF RADIONUCLIDE ANGIOGRAMS [J].
CLEMENTS, IP ;
NELSON, MA ;
OCONNOR, MK ;
BECKER, GP ;
GIBBONS, RJ ;
BROWN, ML .
AMERICAN HEART JOURNAL, 1988, 116 (01) :113-117
[5]  
COTTIN Y, 1995, BRIT HEART J, V73, P61
[6]  
CUTHBERTSON DD, 1994, CIRCULATION, V90, P50
[7]  
FAJARDO LF, 1976, LAB INVEST, V34, P86
[8]   DOXORUBICIN CARDIOTOXICITY - SERIAL ENDOMYOCARDIAL BIOPSIES AND SYSTOLIC-TIME INTERVALS [J].
FRIEDMAN, MA ;
BOZDECH, MJ ;
BILLINGHAM, ME ;
RIDER, AK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (15) :1603-1606
[9]   DETECTION OF EARLY ANTHRACYCLINE CARDIOTOXICITY BY MONITORING THE PEAK FILLING RATE [J].
GANZ, WI ;
SRIDHAR, KS ;
FORNESS, TJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (02) :109-112
[10]  
HAQ MM, 1985, CANCER-AM CANCER SOC, V56, P1361, DOI 10.1002/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO